AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
19 janv. 2023 16h05 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading...
AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
19 déc. 2022 08h00 HE
|
AVITA Medical
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 19, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders
12 déc. 2022 21h11 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and...
AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair
12 déc. 2022 09h15 HE
|
AVITA Medical
VALENCIA, Calif., and MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference
21 nov. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical® to Host Investor Webinar Briefing
16 nov. 2022 21h00 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and...
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
09 nov. 2022 18h45 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
03 nov. 2022 20h15 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical to Announce Third Quarter 2022 Financial Results
20 oct. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...